Physician profile

Emma C Turnquist

Physician Assistant · Saint Paul, MN

NPI 1386032068

$6,475.68

in general payments reported to CMS, 2019-2025

4 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$2,412.00
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$2,410.00
Travel and Lodging$1,175.85
Food and Beverage$477.83

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Genzyme Corporation $6,300.25 2024
Medtronic, INC. $62.49 2023 Gi Genius
Davol INC. $56.52 2023 Phasix Mesh
Janssen Biotech, INC. $56.42 2024 Stelara, Tremfya

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Emma C Turnquist

$6,475.68

in general payments reported 2019-2025

Years
2023-2024
Top company
Genzyme Corporation

https://glasscript.com/doctor/10825293/emma-c-turnquist

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.